<p>OFI Invest Asset Management 在第三季度将其在默克公司（NYSE:MRK - 免费报告）的持股比例提高了 2.5%，根据该公司最近向证券交易委员会的披露。该基金在季度内额外购买了 17,761 股后，持有 733,819 股公司的股票。OFI Invest Asset Management 在默克公司的持股在最近一个季度末价值为 61,589,000 美元。</p>
<p>获取 <strong>默克公司</strong> 的提醒：</p>
<ul>
<li>2026 年股息股票：市场降温时的投资方向</li>
</ul>
<p>其他一些大型投资者也对该股票的持仓进行了调整。DLD Asset Management LP 在第二季度新购入了默克公司的股份，价值约为 2,889,340,000 美元。挪威银行在第二季度购买了默克公司的新头寸，估计价值约为 2,858,570,000 美元。富兰克林资源公司在第二季度将其在默克公司的持仓提高了 23.5%。富兰克林资源公司目前持有 27,032,601 股公司的股票，价值为 2,139,901,000 美元，此前在上个季度额外购买了 5,135,748 股。Arrowstreet Capital Limited Partnership 在第二季度将其在默克公司的持股增加了 35.5%。Arrowstreet Capital Limited Partnership 目前持有 19,456,096 股公司的股票，价值为 1,540,145,000 美元，此前在此期间额外购买了 5,094,088 股。最后，查尔斯·施瓦布投资管理公司在第二季度将其在默克公司的持股增加了 9.4%。查尔斯·施瓦布投资管理公司目前持有 53,865,466 股公司的股票，价值为 4,263,991,000 美元，此前在此期间额外购买了 4,636,183 股。机构投资者和对冲基金持有该公司 76.07% 的股票。</p>
<h2>默克公司的价格表现</h2>
<p>MRK 股票在周二开盘价为 104.79 美元。该公司的市值为 2600.8 亿美元，市盈率为 13.84，市盈增长比率为 0.96，贝塔值为 0.29。该公司的流动比率为 1.66，速动比率为 1.44，债务股本比率为 0.77。该股票的 50 日移动平均价格为 93.74 美元，200 日移动平均价格为 86.43 美元。默克公司的 12 个月低点为 73.31 美元，12 个月高点为 105.84 美元。</p>
<ul>
<li>HIMS 经历了过山车般的旅程。投资者应该入场吗？</li>
</ul>
<p>默克公司（NYSE:MRK - 获取免费报告）最近于 1 月 30 日星期五发布了季度财报。该公司报告季度每股收益为 1.94 美元。默克公司的股本回报率为 44.54%，净利润率为 29.63%。作为一个整体，研究分析师预测默克公司在当前年度将发布 9.01 的每股收益。</p>
<h2>默克公司增加股息</h2>
<p>该公司还最近披露了季度股息，将于 1 月 8 日星期四支付。12 月 15 日星期一的登记股东将获得每股 0.85 美元的股息。这比默克公司之前的季度股息 0.81 美元有所增加。这代表着每年 3.40 美元的股息，收益率为 3.2%。除息日期为 12 月 15 日星期一。默克公司的派息比率目前为 44.91%。</p>
<h2>内部活动</h2>
<ul>
<li>为什么 GRAIL 股票可能是生物技术的下一个重大突破</li>
</ul>
<p>在其他新闻中，执行副总裁 David Michael Williams 在 11 月 3 日星期一以 83.59 美元的平均价格出售了 8,614 股公司的股票，总价值为 720,044.26 美元。交易后，该执行副总裁持有 24,578 股公司的股票，估计价值约为 2,054,475.02 美元。这笔交易代表了其持仓的 25.95% 的减少。该出售在向 SEC 的法律文件中披露，文件可在此链接查看。0.09% 的股票由内部人士持有。</p>
<h2>分析师设定新目标价</h2>
<p>多家券商对 MRK 进行了评估。富国银行将默克公司的评级从 “持平” 上调至 “增持”，并在 11 月 24 日的研究报告中将其目标价从 90.00 美元提高至 125.00 美元。贝伦贝格银行将默克公司的评级从 “买入” 下调至 “持有”，并在 9 月 17 日的研究报告中将其目标价从 100.00 美元下调至 90.00 美元。美国银行在 12 月 15 日的研究报告中将默克公司的目标价从 105.00 美元提高至 120.00 美元，并给予该股票 “买入” 评级。花旗集团在 10 月 13 日的报告中开始覆盖默克公司，给予 “中性” 评级和 95.00 美元的目标价。最后，斯科舍银行在 12 月 4 日的研究报告中将默克公司的目标价从 105.00 美元提高至 120.00 美元，并给予该股票 “行业表现优于大盘” 评级。八位投资分析师对该股票给予 “买入” 评级，八位给予 “持有” 评级，一位给予 “卖出” 评级。根据 MarketBeat 的数据，该公司目前的平均评级为 “持有”，平均目标价为 110.13 美元。</p>
<p><strong>查看我们最新的默克公司股票报告</strong></p>
<h2>默克公司简介</h2>
<p>（免费报告）</p>
<p>默克公司是一家全球生物制药公司，专注于处方药、疫苗、生物治疗和动物健康产品的发现、开发、生产和营销。其产品组合涵盖多个治疗领域，特别强调肿瘤学、疫苗和传染病，以及代谢和慢性病的治疗。其知名产品包括癌症免疫疗法 Keytruda（帕博利珠单抗）和人乳头瘤病毒疫苗 Gardasil；该公司还通过默克动物健康销售一系列兽用药物和疫苗。</p>
<p>公司成立于 19 世纪末，作为美国的</p>
<h2>推荐故事</h2>
<ul>
<li>我们更看好的五只股票，胜过默克公司</li>
<li>请勿删除，立即阅读</li>
<li>投资者警报：微型 “3 美元人工智能奇迹股票” 即将腾飞</li>
<li>资本利得税是否可以扣除任何费用？</li>
<li>巴菲特、盖茨和贝索斯悄悄抛售股票——原因在这里</li>
<li>最后的黄金牛市</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPU1SSw?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPU1SSw"/></p>
<p><em>此即时新闻警报由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资 1000 美元在默克公司吗？</h2>
<p>在考虑默克公司之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄向客户推荐的股票，建议在更广泛的市场注意到之前购买……而默克公司并不在名单上。</p>
<p>虽然默克公司目前在分析师中被评为持有评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

默克

<p>OFI Invest Asset Management 在第三季度将其在默克公司的股份增加了 2.5%，目前持有 733,819 股，价值 6160 万美元。其他主要投资者也调整了他们的持仓，DLD Asset Management、挪威银行和富兰克林资源公司均获得了显著的股份。默克的股票开盘价为 104.79 美元，市值为 2600.8 亿美元。该公司宣布季度股息增加至每股 0.85 美元</p>

<p>OFI Invest Asset Management raised its stake in Merck &amp; Co., Inc. (NYSE:MRK - Free Report) by 2.5% in the third quarter, according to the company in its most recent disclosure with the Securities &amp; Exchange Commission. The fund owned 733,819 shares of the company's stock after acquiring an additional 17,761 shares during the quarter. OFI Invest Asset Management's holdings in Merck &amp; Co., Inc. were worth $61,589,000 at the end of the most recent quarter.</p>
<div class="lb-trans"><p>OFI Invest Asset Management 在第三季度将其在默克公司（NYSE:MRK - 免费报告）的持股比例提高了 2.5%，根据该公司最近向证券交易委员会的披露。该基金在季度内额外购买了 17,761 股后，持有 733,819 股公司的股票。OFI Invest Asset Management 在默克公司的持股在最近一个季度末价值为 61,589,000 美元。</p>
</div><p>Get <strong>Merck &amp; Co., Inc.</strong> alerts:</p>
<div class="lb-trans"><p>获取 <strong>默克公司</strong> 的提醒：</p>
</div><ul>
<li>Dividend Stocks for 2026: Where to Invest as the Market Cools</li>
</ul>
<div class="lb-trans"><ul>
<li>2026 年股息股票：市场降温时的投资方向</li>
</ul>
</div><p>A number of other large investors have also made changes to their positions in the stock. DLD Asset Management LP acquired a new stake in shares of Merck &amp; Co., Inc. during the 2nd quarter worth about $2,889,340,000. Norges Bank purchased a new position in shares of Merck &amp; Co., Inc. during the second quarter valued at approximately $2,858,570,000. Franklin Resources Inc. boosted its position in Merck &amp; Co., Inc. by 23.5% during the second quarter. Franklin Resources Inc. now owns 27,032,601 shares of the company's stock worth $2,139,901,000 after acquiring an additional 5,135,748 shares during the last quarter. Arrowstreet Capital Limited Partnership grew its stake in Merck &amp; Co., Inc. by 35.5% in the 2nd quarter. Arrowstreet Capital Limited Partnership now owns 19,456,096 shares of the company's stock worth $1,540,145,000 after acquiring an additional 5,094,088 shares during the period. Finally, Charles Schwab Investment Management Inc. grew its stake in Merck &amp; Co., Inc. by 9.4% in the 2nd quarter. Charles Schwab Investment Management Inc. now owns 53,865,466 shares of the company's stock worth $4,263,991,000 after acquiring an additional 4,636,183 shares during the period. Institutional investors and hedge funds own 76.07% of the company's stock.</p>
<div class="lb-trans"><p>其他一些大型投资者也对该股票的持仓进行了调整。DLD Asset Management LP 在第二季度新购入了默克公司的股份，价值约为 2,889,340,000 美元。挪威银行在第二季度购买了默克公司的新头寸，估计价值约为 2,858,570,000 美元。富兰克林资源公司在第二季度将其在默克公司的持仓提高了 23.5%。富兰克林资源公司目前持有 27,032,601 股公司的股票，价值为 2,139,901,000 美元，此前在上个季度额外购买了 5,135,748 股。Arrowstreet Capital Limited Partnership 在第二季度将其在默克公司的持股增加了 35.5%。Arrowstreet Capital Limited Partnership 目前持有 19,456,096 股公司的股票，价值为 1,540,145,000 美元，此前在此期间额外购买了 5,094,088 股。最后，查尔斯·施瓦布投资管理公司在第二季度将其在默克公司的持股增加了 9.4%。查尔斯·施瓦布投资管理公司目前持有 53,865,466 股公司的股票，价值为 4,263,991,000 美元，此前在此期间额外购买了 4,636,183 股。机构投资者和对冲基金持有该公司 76.07% 的股票。</p>
</div><h2>Merck &amp; Co., Inc. Price Performance</h2>
<div class="lb-trans"><h2>默克公司的价格表现</h2>
</div><p>MRK stock opened at $104.79 on Tuesday. The company has a market cap of $260.08 billion, a PE ratio of 13.84, a price-to-earnings-growth ratio of 0.96 and a beta of 0.29. The company has a current ratio of 1.66, a quick ratio of 1.44 and a debt-to-equity ratio of 0.77. The stock has a 50-day moving average price of $93.74 and a two-hundred day moving average price of $86.43. Merck &amp; Co., Inc. has a 12-month low of $73.31 and a 12-month high of $105.84.</p>
<div class="lb-trans"><p>MRK 股票在周二开盘价为 104.79 美元。该公司的市值为 2600.8 亿美元，市盈率为 13.84，市盈增长比率为 0.96，贝塔值为 0.29。该公司的流动比率为 1.66，速动比率为 1.44，债务股本比率为 0.77。该股票的 50 日移动平均价格为 93.74 美元，200 日移动平均价格为 86.43 美元。默克公司的 12 个月低点为 73.31 美元，12 个月高点为 105.84 美元。</p>
</div><ul>
<li>HIMS Has Been a Roller Coaster Ride. Should Investors Hop On?</li>
</ul>
<div class="lb-trans"><ul>
<li>HIMS 经历了过山车般的旅程。投资者应该入场吗？</li>
</ul>
</div><p>Merck &amp; Co., Inc. (NYSE:MRK - Get Free Report) last released its quarterly earnings data on Friday, January 30th. The company reported $1.94 earnings per share for the quarter. Merck &amp; Co., Inc. had a return on equity of 44.54% and a net margin of 29.63%. As a group, research analysts predict that Merck &amp; Co., Inc. will post 9.01 EPS for the current year.</p>
<div class="lb-trans"><p>默克公司（NYSE:MRK - 获取免费报告）最近于 1 月 30 日星期五发布了季度财报。该公司报告季度每股收益为 1.94 美元。默克公司的股本回报率为 44.54%，净利润率为 29.63%。作为一个整体，研究分析师预测默克公司在当前年度将发布 9.01 的每股收益。</p>
</div><h2>Merck &amp; Co., Inc. Increases Dividend</h2>
<div class="lb-trans"><h2>默克公司增加股息</h2>
</div><p>The firm also recently disclosed a quarterly dividend, which will be paid on Thursday, January 8th. Shareholders of record on Monday, December 15th will be paid a dividend of $0.85 per share. This is an increase from Merck &amp; Co., Inc.'s previous quarterly dividend of $0.81. This represents a $3.40 annualized dividend and a yield of 3.2%. The ex-dividend date is Monday, December 15th. Merck &amp; Co., Inc.'s payout ratio is presently 44.91%.</p>
<div class="lb-trans"><p>该公司还最近披露了季度股息，将于 1 月 8 日星期四支付。12 月 15 日星期一的登记股东将获得每股 0.85 美元的股息。这比默克公司之前的季度股息 0.81 美元有所增加。这代表着每年 3.40 美元的股息，收益率为 3.2%。除息日期为 12 月 15 日星期一。默克公司的派息比率目前为 44.91%。</p>
</div><h2>Insider Activity</h2>
<div class="lb-trans"><h2>内部活动</h2>
</div><ul>
<li>Why GRAIL Stock Could Be Biotech’s Next Big Breakout</li>
</ul>
<div class="lb-trans"><ul>
<li>为什么 GRAIL 股票可能是生物技术的下一个重大突破</li>
</ul>
</div><p>In other news, EVP David Michael Williams sold 8,614 shares of the firm's stock in a transaction on Monday, November 3rd. The shares were sold at an average price of $83.59, for a total value of $720,044.26. Following the transaction, the executive vice president owned 24,578 shares of the company's stock, valued at approximately $2,054,475.02. This trade represents a 25.95% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link. 0.09% of the stock is owned by insiders.</p>
<div class="lb-trans"><p>在其他新闻中，执行副总裁 David Michael Williams 在 11 月 3 日星期一以 83.59 美元的平均价格出售了 8,614 股公司的股票，总价值为 720,044.26 美元。交易后，该执行副总裁持有 24,578 股公司的股票，估计价值约为 2,054,475.02 美元。这笔交易代表了其持仓的 25.95% 的减少。该出售在向 SEC 的法律文件中披露，文件可在此链接查看。0.09% 的股票由内部人士持有。</p>
</div><h2>Analysts Set New Price Targets</h2>
<div class="lb-trans"><h2>分析师设定新目标价</h2>
</div><p>A number of brokerages have weighed in on MRK. Wells Fargo &amp; Company raised Merck &amp; Co., Inc. from an &#34;equal weight&#34; rating to an &#34;overweight&#34; rating and increased their price target for the stock from $90.00 to $125.00 in a research note on Monday, November 24th. Berenberg Bank lowered Merck &amp; Co., Inc. from a &#34;buy&#34; rating to a &#34;hold&#34; rating and dropped their target price for the company from $100.00 to $90.00 in a research note on Wednesday, September 17th. Bank of America raised their price target on Merck &amp; Co., Inc. from $105.00 to $120.00 and gave the stock a &#34;buy&#34; rating in a research note on Monday, December 15th. Citigroup started coverage on Merck &amp; Co., Inc. in a report on Monday, October 13th. They issued a &#34;neutral&#34; rating and a $95.00 price target for the company. Finally, Scotiabank raised their target price on shares of Merck &amp; Co., Inc. from $105.00 to $120.00 and gave the stock a &#34;sector outperform&#34; rating in a research report on Thursday, December 4th. Eight investment analysts have rated the stock with a Buy rating, eight have issued a Hold rating and one has assigned a Sell rating to the company's stock. According to data from MarketBeat, the company currently has an average rating of &#34;Hold&#34; and an average price target of $110.13.</p>
<div class="lb-trans"><p>多家券商对 MRK 进行了评估。富国银行将默克公司的评级从 “持平” 上调至 “增持”，并在 11 月 24 日的研究报告中将其目标价从 90.00 美元提高至 125.00 美元。贝伦贝格银行将默克公司的评级从 “买入” 下调至 “持有”，并在 9 月 17 日的研究报告中将其目标价从 100.00 美元下调至 90.00 美元。美国银行在 12 月 15 日的研究报告中将默克公司的目标价从 105.00 美元提高至 120.00 美元，并给予该股票 “买入” 评级。花旗集团在 10 月 13 日的报告中开始覆盖默克公司，给予 “中性” 评级和 95.00 美元的目标价。最后，斯科舍银行在 12 月 4 日的研究报告中将默克公司的目标价从 105.00 美元提高至 120.00 美元，并给予该股票 “行业表现优于大盘” 评级。八位投资分析师对该股票给予 “买入” 评级，八位给予 “持有” 评级，一位给予 “卖出” 评级。根据 MarketBeat 的数据，该公司目前的平均评级为 “持有”，平均目标价为 110.13 美元。</p>
</div><p><strong>View Our Latest Stock Report on Merck &amp; Co., Inc.</strong></p>
<div class="lb-trans"><p><strong>查看我们最新的默克公司股票报告</strong></p>
</div><h2>Merck &amp; Co., Inc. Profile</h2>
<div class="lb-trans"><h2>默克公司简介</h2>
</div><p>(Free Report)</p>
<div class="lb-trans"><p>（免费报告）</p>
</div><p>Merck &amp; Co, Inc is a global biopharmaceutical company engaged in the discovery, development, manufacture and marketing of prescription medicines, vaccines, biologic therapies and animal health products. Its portfolio spans multiple therapeutic areas with a particular emphasis on oncology, vaccines and infectious disease, as well as therapies for metabolic and chronic conditions. Among its well-known products are the cancer immunotherapy Keytruda (pembrolizumab) and the human papillomavirus vaccine Gardasil; the company also markets a range of medicines and vaccines for veterinary use through Merck Animal Health.</p>
<div class="lb-trans"><p>默克公司是一家全球生物制药公司，专注于处方药、疫苗、生物治疗和动物健康产品的发现、开发、生产和营销。其产品组合涵盖多个治疗领域，特别强调肿瘤学、疫苗和传染病，以及代谢和慢性病的治疗。其知名产品包括癌症免疫疗法 Keytruda（帕博利珠单抗）和人乳头瘤病毒疫苗 Gardasil；该公司还通过默克动物健康销售一系列兽用药物和疫苗。</p>
</div><p>Founded in the late 19th century as the U.S.</p>
<div class="lb-trans"><p>公司成立于 19 世纪末，作为美国的</p>
</div><h2>Recommended Stories</h2>
<div class="lb-trans"><h2>推荐故事</h2>
</div><ul>
<li>Five stocks we like better than Merck &amp; Co., Inc.</li>
<li>Do not delete, read immediately</li>
<li>INVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting Off</li>
<li>Can Any Expenses Be Deducted From Capital Gains Tax?</li>
<li>Buffett, Gates and Bezos Quietly Dumping Stocks—Here's Why</li>
<li>The Last Gold Bull Market</li>
</ul>
<div class="lb-trans"><ul>
<li>我们更看好的五只股票，胜过默克公司</li>
<li>请勿删除，立即阅读</li>
<li>投资者警报：微型 “3 美元人工智能奇迹股票” 即将腾飞</li>
<li>资本利得税是否可以扣除任何费用？</li>
<li>巴菲特、盖茨和贝索斯悄悄抛售股票——原因在这里</li>
<li>最后的黄金牛市</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPU1SSw" alt="" original-src="https://www.marketbeat.com/scripts/SECFilingChart.ashx?Prefix=NYSE&amp;Symbol=MRK"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻警报由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Merck &amp; Co., Inc. Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1000 美元在默克公司吗？</h2>
</div><p>Before you consider Merck &amp; Co., Inc., you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑默克公司之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Merck &amp; Co., Inc. wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄向客户推荐的股票，建议在更广泛的市场注意到之前购买……而默克公司并不在名单上。</p>
</div><p>While Merck &amp; Co., Inc. currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然默克公司目前在分析师中被评为持有评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

默克公司（Merck & Co., Inc.）的股票 $MRK 被 OFI Invest 资产管理公司购买